Russian Severe Asthma Registry
RSAR
The Russian Registry of Patients With Severe Asthma to Collect Anonymous Long-term Evidence
1 other identifier
observational
7,000
1 country
1
Brief Summary
The Russian Severe Asthma Registry is a Russian initiative to collect anonymous long-term evidence for patients with severe asthma in Russia
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2018
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 30, 2018
CompletedFirst Submitted
Initial submission to the registry
May 4, 2018
CompletedFirst Posted
Study publicly available on registry
August 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2022
CompletedAugust 10, 2018
July 1, 2018
4.8 years
May 4, 2018
August 8, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
• Percentage of patients with severe asthma according frequency of exacerbations at the time of study enrollment
Percentage of patients with severe asthma according frequency of exacerbations (1, 2, ≥3 exacerbations) at the time of study enrollment
03.2018 till 11.2022.
Secondary Outcomes (82)
• Percentage of patients with severe asthma according frequency of exacerbations at the 1 year of follow-up;
03.2019 till 11.2022.
Percentage of patients with severe asthma according frequency of exacerbations at the 2 year of follow-up;
03.2020 till 11.2022.
• Percentage of patients with severe asthma according frequency of exacerbations at the 3 year of follow-up;
03.2021 till 11.2022.
• Percentage of patients with severe asthma according frequency of exacerbations (1, 2, ≥3 exacerbations) at the 4 year of follow-up;
03.2022 till 11.2022.
• Percentage of patients with severe asthma according concomitant diseases at the time of study enrollment
03.2018 till 11.2022.
- +77 more secondary outcomes
Eligibility Criteria
Patients receiving step 4 and 5 treatment (according to GINA, 2017) in accordance with the uncontrolled asthma severity (J.45) in health facilities
You may qualify if:
- Patients aged 12 years or older.
- Patients with confirmed diagnosis of severe asthma.
- Patients receiving treatment according to GINA step 5 or uncontrolled for 4 step. Uncontrolled patients are defined as having symptoms of severe asthma or frequent exacerbations .
- Signed informed consent.
You may not qualify if:
- Patients currently participating in clinical trials at the time of enrolment
- Intermittent, mild, moderate BA, before verification of the diagnosis.
- COPD.
- Diseases of the respiratory system, such as tuberculosis, sarcoidosis, IPF, lung cancer.
- Vasculitis, systemic connective tissue diseases.
- Neoplasm.
- Written refusal of the patient to participate in the study after signing an informed consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
City hospital 52
Moscow, 123182, Russia
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Andrey S Belevskiy, Ph.D.
Russian Respiratory Society
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 5 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 4, 2018
First Posted
August 1, 2018
Study Start
March 30, 2018
Primary Completion
December 31, 2022
Study Completion
December 31, 2022
Last Updated
August 10, 2018
Record last verified: 2018-07
Data Sharing
- IPD Sharing
- Will not share